June 2018

New Product - Trulicity

Dulaglutide (rch) (Trulicity) is an engineered long-acting GLP-1 receptor agonist, with a GLP-1 analogue sequence covalently linked to a modified human IgG4 heavy chain fragment (Fc). Trulicity is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: as monotherapy; in combination with the oral glucose lowering medications metformin, metformin and sulfonylurea, metformin and thiazolidinedione; in combination with prandial insulin, with or without metformin. Trulicity solution for injection (1.5 mg/0.5 mL) is available as a single dose, ready to use prefilled pen (autoinjector) in a pack size of 4.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au